Intrinsic value of Halozyme Therapeutics - HALO

Previous Close

$18.95

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$18.95

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of HALO stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  8.89
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  147
  235
  363
  543
  789
  1,112
  1,529
  2,053
  2,696
  3,469
  4,381
  5,440
  6,651
  8,017
  9,539
  11,216
  13,047
  15,029
  17,158
  19,433
  21,848
  24,402
  27,090
  29,912
  32,866
  35,951
  39,168
  42,518
  46,004
  49,628
  53,395
Variable operating expenses, $m
 
  283
  438
  654
  949
  1,339
  1,841
  2,472
  3,245
  4,176
  5,275
  6,550
  8,008
  9,652
  11,485
  13,504
  15,708
  18,094
  20,659
  23,397
  26,305
  29,380
  32,617
  36,014
  39,570
  43,285
  47,158
  51,192
  55,389
  59,753
  64,288
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  230
  283
  438
  654
  949
  1,339
  1,841
  2,472
  3,245
  4,176
  5,275
  6,550
  8,008
  9,652
  11,485
  13,504
  15,708
  18,094
  20,659
  23,397
  26,305
  29,380
  32,617
  36,014
  39,570
  43,285
  47,158
  51,192
  55,389
  59,753
  64,288
Operating income, $m
  -83
  -48
  -74
  -111
  -161
  -227
  -312
  -419
  -550
  -708
  -894
  -1,110
  -1,357
  -1,635
  -1,946
  -2,288
  -2,662
  -3,066
  -3,500
  -3,964
  -4,457
  -4,978
  -5,526
  -6,102
  -6,705
  -7,334
  -7,990
  -8,674
  -9,385
  -10,124
  -10,893
EBITDA, $m
  -81
  -47
  -72
  -108
  -157
  -221
  -304
  -408
  -535
  -689
  -870
  -1,080
  -1,321
  -1,592
  -1,894
  -2,227
  -2,591
  -2,985
  -3,408
  -3,859
  -4,339
  -4,846
  -5,380
  -5,941
  -6,527
  -7,140
  -7,779
  -8,444
  -9,136
  -9,856
  -10,604
Interest expense (income), $m
  4
  7
  0
  2
  4
  7
  11
  16
  22
  30
  40
  51
  64
  79
  95
  114
  134
  157
  181
  207
  235
  264
  295
  328
  363
  399
  436
  476
  517
  559
  603
Earnings before tax, $m
  -102
  -55
  -74
  -113
  -165
  -234
  -323
  -435
  -572
  -738
  -933
  -1,161
  -1,421
  -1,714
  -2,041
  -2,402
  -2,796
  -3,222
  -3,681
  -4,171
  -4,692
  -5,242
  -5,822
  -6,430
  -7,067
  -7,733
  -8,427
  -9,149
  -9,901
  -10,683
  -11,496
Tax expense, $m
  1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -103
  -55
  -74
  -113
  -165
  -234
  -323
  -435
  -572
  -738
  -933
  -1,161
  -1,421
  -1,714
  -2,041
  -2,402
  -2,796
  -3,222
  -3,681
  -4,171
  -4,692
  -5,242
  -5,822
  -6,430
  -7,067
  -7,733
  -8,427
  -9,149
  -9,901
  -10,683
  -11,496

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  205
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  262
  91
  141
  211
  306
  431
  593
  796
  1,045
  1,345
  1,699
  2,109
  2,579
  3,109
  3,699
  4,349
  5,059
  5,827
  6,653
  7,535
  8,472
  9,462
  10,504
  11,598
  12,744
  13,940
  15,187
  16,486
  17,838
  19,243
  20,704
Adjusted assets (=assets-cash), $m
  57
  91
  141
  211
  306
  431
  593
  796
  1,045
  1,345
  1,699
  2,109
  2,579
  3,109
  3,699
  4,349
  5,059
  5,827
  6,653
  7,535
  8,472
  9,462
  10,504
  11,598
  12,744
  13,940
  15,187
  16,486
  17,838
  19,243
  20,704
Revenue / Adjusted assets
  2.579
  2.582
  2.574
  2.573
  2.578
  2.580
  2.578
  2.579
  2.580
  2.579
  2.579
  2.579
  2.579
  2.579
  2.579
  2.579
  2.579
  2.579
  2.579
  2.579
  2.579
  2.579
  2.579
  2.579
  2.579
  2.579
  2.579
  2.579
  2.579
  2.579
  2.579
Average production assets, $m
  4
  6
  10
  15
  21
  30
  41
  55
  73
  94
  118
  147
  180
  216
  258
  303
  352
  406
  463
  525
  590
  659
  731
  808
  887
  971
  1,058
  1,148
  1,242
  1,340
  1,442
Working capital, $m
  202
  22
  35
  52
  75
  106
  145
  195
  256
  330
  416
  517
  632
  762
  906
  1,065
  1,239
  1,428
  1,630
  1,846
  2,076
  2,318
  2,574
  2,842
  3,122
  3,415
  3,721
  4,039
  4,370
  4,715
  5,073
Total debt, $m
  217
  5
  50
  113
  198
  311
  457
  639
  864
  1,133
  1,452
  1,822
  2,244
  2,721
  3,252
  3,837
  4,476
  5,168
  5,911
  6,705
  7,547
  8,439
  9,377
  10,361
  11,392
  12,469
  13,592
  14,761
  15,977
  17,242
  18,557
Total liabilities, $m
  294
  82
  127
  190
  275
  388
  534
  716
  941
  1,210
  1,529
  1,899
  2,321
  2,798
  3,329
  3,914
  4,553
  5,245
  5,988
  6,782
  7,624
  8,516
  9,454
  10,438
  11,469
  12,546
  13,669
  14,838
  16,054
  17,319
  18,634
Total equity, $m
  -32
  9
  14
  21
  31
  43
  59
  80
  105
  134
  170
  211
  258
  311
  370
  435
  506
  583
  665
  754
  847
  946
  1,050
  1,160
  1,274
  1,394
  1,519
  1,649
  1,784
  1,924
  2,070
Total liabilities and equity, $m
  262
  91
  141
  211
  306
  431
  593
  796
  1,046
  1,344
  1,699
  2,110
  2,579
  3,109
  3,699
  4,349
  5,059
  5,828
  6,653
  7,536
  8,471
  9,462
  10,504
  11,598
  12,743
  13,940
  15,188
  16,487
  17,838
  19,243
  20,704
Debt-to-equity ratio
  -6.781
  0.560
  3.540
  5.350
  6.480
  7.210
  7.700
  8.030
  8.260
  8.430
  8.550
  8.630
  8.700
  8.750
  8.790
  8.820
  8.850
  8.870
  8.880
  8.900
  8.910
  8.920
  8.930
  8.930
  8.940
  8.940
  8.950
  8.950
  8.960
  8.960
  8.960
Adjusted equity ratio
  -4.158
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -103
  -55
  -74
  -113
  -165
  -234
  -323
  -435
  -572
  -738
  -933
  -1,161
  -1,421
  -1,714
  -2,041
  -2,402
  -2,796
  -3,222
  -3,681
  -4,171
  -4,692
  -5,242
  -5,822
  -6,430
  -7,067
  -7,733
  -8,427
  -9,149
  -9,901
  -10,683
  -11,496
Depreciation, amort., depletion, $m
  2
  1
  2
  3
  4
  6
  8
  11
  15
  19
  24
  29
  36
  43
  52
  61
  70
  81
  93
  105
  118
  132
  146
  162
  177
  194
  212
  230
  248
  268
  288
Funds from operations, $m
  -32
  -54
  -72
  -110
  -161
  -228
  -315
  -424
  -558
  -719
  -910
  -1,131
  -1,385
  -1,671
  -1,990
  -2,341
  -2,725
  -3,141
  -3,589
  -4,066
  -4,574
  -5,110
  -5,675
  -6,269
  -6,890
  -7,539
  -8,215
  -8,920
  -9,653
  -10,415
  -11,208
Change in working capital, $m
  18
  8
  12
  17
  23
  31
  40
  50
  61
  73
  87
  101
  115
  130
  145
  159
  174
  188
  202
  216
  229
  243
  255
  268
  281
  293
  306
  318
  331
  344
  358
Cash from operations, $m
  -50
  -62
  -85
  -127
  -184
  -259
  -354
  -473
  -619
  -793
  -996
  -1,232
  -1,500
  -1,800
  -2,134
  -2,501
  -2,899
  -3,330
  -3,791
  -4,282
  -4,803
  -5,353
  -5,931
  -6,537
  -7,170
  -7,832
  -8,521
  -9,238
  -9,984
  -10,760
  -11,566
Maintenance CAPEX, $m
  0
  -1
  -1
  -2
  -3
  -4
  -6
  -8
  -11
  -15
  -19
  -24
  -29
  -36
  -43
  -52
  -61
  -70
  -81
  -93
  -105
  -118
  -132
  -146
  -162
  -177
  -194
  -212
  -230
  -248
  -268
New CAPEX, $m
  -3
  -2
  -3
  -5
  -7
  -9
  -11
  -14
  -17
  -21
  -25
  -29
  -33
  -37
  -41
  -45
  -49
  -54
  -58
  -61
  -65
  -69
  -73
  -76
  -80
  -83
  -87
  -90
  -94
  -98
  -102
Cash from investing activities, $m
  -77
  -3
  -4
  -7
  -10
  -13
  -17
  -22
  -28
  -36
  -44
  -53
  -62
  -73
  -84
  -97
  -110
  -124
  -139
  -154
  -170
  -187
  -205
  -222
  -242
  -260
  -281
  -302
  -324
  -346
  -370
Free cash flow, $m
  -127
  -65
  -89
  -134
  -193
  -272
  -372
  -496
  -647
  -828
  -1,040
  -1,284
  -1,562
  -1,873
  -2,219
  -2,597
  -3,009
  -3,454
  -3,930
  -4,436
  -4,973
  -5,540
  -6,135
  -6,759
  -7,412
  -8,092
  -8,802
  -9,540
  -10,308
  -11,106
  -11,935
Issuance/(repayment) of debt, $m
  149
  -195
  45
  63
  86
  113
  145
  183
  224
  270
  318
  370
  423
  477
  531
  585
  639
  692
  743
  794
  843
  891
  938
  985
  1,031
  1,077
  1,123
  1,169
  1,216
  1,265
  1,315
Issuance/(repurchase) of shares, $m
  2
  284
  79
  120
  174
  246
  339
  455
  597
  768
  969
  1,202
  1,468
  1,767
  2,100
  2,467
  2,867
  3,299
  3,764
  4,259
  4,785
  5,341
  5,926
  6,540
  7,182
  7,852
  8,551
  9,279
  10,037
  10,824
  11,642
Cash from financing (excl. dividends), $m  
  151
  89
  124
  183
  260
  359
  484
  638
  821
  1,038
  1,287
  1,572
  1,891
  2,244
  2,631
  3,052
  3,506
  3,991
  4,507
  5,053
  5,628
  6,232
  6,864
  7,525
  8,213
  8,929
  9,674
  10,448
  11,253
  12,089
  12,957
Total cash flow (excl. dividends), $m
  23
  24
  35
  49
  66
  88
  113
  142
  174
  210
  247
  287
  328
  370
  413
  455
  496
  537
  578
  617
  655
  692
  729
  765
  801
  837
  872
  908
  945
  983
  1,021
Retained Cash Flow (-), $m
  75
  -284
  -79
  -120
  -174
  -246
  -339
  -455
  -597
  -768
  -969
  -1,202
  -1,468
  -1,767
  -2,100
  -2,467
  -2,867
  -3,299
  -3,764
  -4,259
  -4,785
  -5,341
  -5,926
  -6,540
  -7,182
  -7,852
  -8,551
  -9,279
  -10,037
  -10,824
  -11,642
Prev. year cash balance distribution, $m
 
  188
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  -72
  -45
  -71
  -108
  -159
  -226
  -313
  -423
  -558
  -721
  -914
  -1,139
  -1,397
  -1,688
  -2,012
  -2,370
  -2,762
  -3,186
  -3,643
  -4,130
  -4,649
  -5,197
  -5,775
  -6,381
  -7,016
  -7,679
  -8,371
  -9,091
  -9,841
  -10,621
Discount rate, %
 
  6.30
  6.62
  6.95
  7.29
  7.66
  8.04
  8.44
  8.86
  9.31
  9.77
  10.26
  10.78
  11.31
  11.88
  12.47
  13.10
  13.75
  14.44
  15.16
  15.92
  16.72
  17.55
  18.43
  19.35
  20.32
  21.33
  22.40
  23.52
  24.70
  25.93
PV of cash for distribution, $m
 
  -68
  -39
  -58
  -81
  -110
  -142
  -178
  -214
  -251
  -284
  -312
  -334
  -347
  -351
  -345
  -331
  -309
  -281
  -249
  -215
  -181
  -148
  -118
  -91
  -69
  -50
  -36
  -25
  -16
  -11
Current shareholders' claim on cash, %
  100
  50.0
  5.2
  0.5
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

FINANCIAL RATIOS  of  Halozyme Therapeutics (HALO)

Valuation Ratios
P/E Ratio -23.8
Price to Sales 16.7
Price to Book -76.7
Price to Tangible Book
Price to Cash Flow -49.1
Price to Free Cash Flow -46.3
Growth Rates
Sales Growth Rate 8.9%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 50%
Cap. Spend. - 3 Yr. Gr. Rate 8.4%
Financial Strength
Quick Ratio 12
Current Ratio 0
LT Debt to Equity -625%
Total Debt to Equity -678.1%
Interest Coverage -25
Management Effectiveness
Return On Assets -44.6%
Ret/ On Assets - 3 Yr. Avg. -36.4%
Return On Total Capital -74.1%
Ret/ On T. Cap. - 3 Yr. Avg. -73.8%
Return On Equity -1872.7%
Return On Equity - 3 Yr. Avg. -865.5%
Asset Turnover 0.7
Profitability Ratios
Gross Margin 76.9%
Gross Margin - 3 Yr. Avg. 75.4%
EBITDA Margin -65.3%
EBITDA Margin - 3 Yr. Avg. -56.2%
Operating Margin -56.5%
Oper. Margin - 3 Yr. Avg. -53.7%
Pre-Tax Margin -69.4%
Pre-Tax Margin - 3 Yr. Avg. -61.3%
Net Profit Margin -70.1%
Net Profit Margin - 3 Yr. Avg. -61.5%
Effective Tax Rate -1%
Eff/ Tax Rate - 3 Yr. Avg. -0.3%
Payout Ratio 0%

HALO stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the HALO stock intrinsic value calculation we used $147 million for the last fiscal year's total revenue generated by Halozyme Therapeutics. The default revenue input number comes from 2016 income statement of Halozyme Therapeutics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our HALO stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 6.3%, whose default value for HALO is calculated based on our internal credit rating of Halozyme Therapeutics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Halozyme Therapeutics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of HALO stock the variable cost ratio is equal to 120.4%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for HALO stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Halozyme Therapeutics.

Corporate tax rate of 27% is the nominal tax rate for Halozyme Therapeutics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the HALO stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for HALO are equal to 2.7%.

Life of production assets of 2 years is the average useful life of capital assets used in Halozyme Therapeutics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for HALO is equal to 9.5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-32 million for Halozyme Therapeutics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 145.114 million for Halozyme Therapeutics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Halozyme Therapeutics at the current share price and the inputted number of shares is $2.7 billion.

RELATED COMPANIES Price Int.Val. Rating
PFE Pfizer 36.93 28.29  sell
ABBV AbbVie 106.49 30.60  str.sell
LLY Eli Lilly 85.44 111.38  buy
JNJ Johnson&Johnso 148.14 146.14  hold
MRK Merck&Co 61.25 30.23  sell
FGEN FibroGen 49.90 0.46  str.sell
PPHM Peregrine Phar 4.22 0.29  str.sell

COMPANY NEWS

▶ Stocks To Watch: Halozyme Therapeutics Sees RS Rating Rise To 92   [Jan-11-18 03:00AM  Investor's Business Daily]
▶ 3 Top Stocks Wall Street Is Overlooking   [Dec-26-17 10:30AM  Motley Fool]
▶ Analyst Recommendations for Alexion in December 2017   [Dec-11-17 09:02AM  Market Realist]
▶ Halozyme Therapeutics beats 3Q profit forecasts   [Nov-07-17 06:01PM  Associated Press]
▶ 3 Monster Stocks in the Making   [06:03AM  Motley Fool]
▶ 1 Great Biotech Stock You Have Never Heard Of   [Sep-29-17 11:34AM  Motley Fool]
▶ [$$] Charting the Market   [Sep-15-17 11:33PM  Barrons.com]
▶ Stocks Generating Improved Relative Strength: Halozyme Therapeutics   [Aug-30-17 03:00AM  Investor's Business Daily]
▶ Halozyme Therapeutics reports 2Q loss   [Aug-08-17 11:40PM  Associated Press]
Financial statements of HALO
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.